Amarin | AMRN - Operating Expenses


Amarin reported $51.48M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amarin USD 51.48M 113K Dec/2025
AstraZeneca USD 8.18B 4.35B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
DBV Technologies USD 47.9M 2.2M Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novartis USD 9.29B 507M Mar/2026